International Journal of Pharmaceutical Compounding

A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

LEARN MORE

Basics of Compounding: The Revised "Not to Compound List"

Author(s): Allen Loyd V Jr

Issue: Jan/Feb 2015 - Volume 19, Number 1
View All Articles in Issue

Page(s): 57-58

Note: Electronic version includes supplemental material.

Download in electronic PDF format for $75

Abstract:

Related Keywords: Loyd V. Allen, Jr., PhD, RPh, U.S. Food and Drug Administration, FDA, drug safety, withdrawn drugs, not to compound list

Related Categories: LEGAL, DISCONTINUED FORMULATIONS

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Basics of Compounding: The Revised "Not to Compound List" Allen Loyd V Jr	Jan/Feb 2015 Pg. 57-58
Compounding in the Pharmacy Curriculum: Beyond the Basics Hinkle Amanda R, Newton Gail D	May/Jun 2004 Pg. 181-185
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List") Allen Loyd V Jr, Ashworth Lisa D	Jan/Feb 2005 Pg. 44-46
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Cabaleiro Joe	Sep/Oct 2021 Pg. 358-362
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
Basics of Compounding: The "Negative" List Allen Loyd V	Jul/Aug 2015 Pg. 311-313
The "Lists": What Do They Mean? Voliva John	Nov/Dec 2016 Pg. 477-479
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Blankenship Cynthia E	Sep/Oct 2014 Pg. 379-380
The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013 Lutz Eugene, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc	Jan/Feb 2014 Pg. 6-12
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
Current Topical Treatments in Wound Healing - Part 1 Helmke Christopher D	Jul/Aug 2004 Pg. 269-274
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products Uttaro Elizabeth, Zhao Fang, Schweighardt Anne	Sep/Oct 2021 Pg. 364-371
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
Return to Top